Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK NCRI R-CHOP 14 versus 21 phase 3 trial

Mary Gleeson, Nicholas Counsell, David Cunningham*, Anthony Lawrie, Laura Clifton-Hadley, Eliza Hawkes, Andrew McMillan, Kirit M Ardeshna, Cathy Burton, Nick Chadwick, Joanna Gambell, Paul Smith, Paul Mouncey, Christopher Pocock, John Radford, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, David Linch The Royal Marsden Hospital, London and Surrey, United Kingdom, Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, United Kingdom, Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Melbourne, Australia, Eastern Health, Melbourne Australia, Nottingham City Hospital, Nottingham, United Kingdom, University College London, London, United Kingdom, Mount Vernon Cancer Centre, Northwood, United Kingdom, HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, East Kent Hospitals, Canterbury, United Kingdom, The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Western General Hospital, Edinburgh, United Kingdom, Torbay Hospital, Torquay, United Kingdom, Royal Cornwall Hospital, Truro, United Kingdom, Cancer Research UK Centre, Southampton, United Kingdom